Off Label NCCN denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for off label nccn are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for an Off-Label NCCN-Supported Treatment — and How to Appeal a Denial

Aetna requires prior authorization (PA) for most specialty and biologic drugs, and the requirement is even more consistent for off-label use. A PA-required denial means either the PA was not obtained before the drug was dispensed or administered, or the PA was requested and denied. The PA process is Aetna's gate for verifying that clinical criteria in its coverage policy are met. Understanding exactly which criteria were cited in the denial is essential to a successful appeal.

### Why This Denial Is Appealable

If the PA was denied (rather than simply not filed), the denial must be based on Aetna's published criteria — and if the clinical record satisfies those criteria, the denial is incorrect and reversible. NCCN-supported off-label uses are covered under Aetna's policies when the documentation supports the applicable NCCN category and the plan's own clinical criteria. ACA §2719 and ERISA §503 guarantee full internal appeal rights and, if that fails, binding independent external review. A PA denial is not a final answer.

If the PA was simply not obtained in advance (retroactive claim), the appeal should focus on demonstrating that prior authorization would have been granted had it been sought, and that denial of coverage is a disproportionate remedy.

### Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. Standard appeals must be resolved within 30–60 days; urgent cases within 72 hours.
• External review: File within approximately four months of the final internal denial. The IRO's decision is binding on Aetna.
• Expedited option: For ongoing or urgent treatment, request expedited review in writing at both the internal and external stages.

### Documentation to Gather

1. Diagnosis and staging records — pathology, molecular testing, imaging, and clinical notes confirming the diagnosis and the specific characteristics that match the NCCN-listed indication. 2. NCCN Compendium support — the NCCN category and evidence rating for the off-label use, with the edition date. Your oncologist should obtain this from NCCN directly. 3. Prior treatment history — dated records of all prior therapies tried, with documented outcomes, especially if the PA criteria include step-therapy or failure-of-prior-treatment requirements. 4. Clinical severity documentation — performance-status assessments, laboratory markers, or other objective measures recorded in the chart. 5. Prescriber medical-necessity letter — your physician should address each criterion in Aetna's Clinical Policy Bulletin for this drug or drug class and map the chart evidence to each.

### Criteria-Mapping Structure

Obtain Aetna's complete prior authorization criteria for this drug (available in the CPB or through Aetna's provider portal) and respond criterion by criterion:

| PA Criterion from Aetna Policy | Chart Evidence Meeting It | |---|---| | Diagnosis confirmed with required characteristics | [Pathology / molecular report, date] | | NCCN Compendium listing for this indication | [NCCN category, indication, edition] | | Prior therapy requirements satisfied | [Drug, dates, documented response or failure] | | Prescriber specialty requirement | [Prescribing physician's credentials] |

A complete criterion-by-criterion response dramatically increases the likelihood that either Aetna will reverse the denial or an IRO will do so on external review.